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Abstract
Background: Adjunctive uterotonic in patients at risk of  primary post-partum haemorrhage may reduce its incidence. 
Objective: To compare the effectiveness and safety of  adjunctive rectal misoprostol with adjunctive intravenous oxy-
tocin for the prevention of  primary post-partum haemorrhage in at risk patients.
Materials and methods: A total of  122 patients with risk factors for uterine atony were allocated to receive either 
600μg of  rectal misoprostol (n= 61) or 20IU of  oxytocin infusion (n=61) after routine management of  third stage of  
labour.  Post-partum blood loss was measured using differential delivery towel and pad weighing. 
Results: There was similarity in the estimated post-partum blood loss, with no significant difference in the mean 
post-partum hematocrit levels between the adjunctive rectal misoprostol group and oxytocin infusion group (P=0.712). 
There was no difference in the need for additional intervention of  uterotonics between the two groups. There were 
however, higher incidences of  shivering and pyrexia among those that received misoprostol compared with the oxy-
tocin group. 
Conclusion: Rectal misoprostol is as effective and safe as oxytocin when used as an adjunctive uterotonic in prevent-
ing primary post-partum haemorrhage in patients with risk factors for uterine atony after active management of  third 
stage of  labour. 
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Introduction
Post-partum haemorrhage (PPH) is an important cause 
of  maternal morbidity and mortality especially in the de-
veloping countries.1 Post-partum Haemorrhage (PPH) is 
commonly defined as a blood loss of  500 ml or more 
after vaginal delivery2  or blood loss in excess of  1000ml 
after caesarean delivery.3 For clinical purposes however, 
any blood loss enough to cause hemodynamic instability 
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is also termed post-partum haemorrhage.4  It is said to be 
“primary” when it occurs within 24 hours of  delivery and 
“secondary” when the bleeding occurs after 24 hours of  
delivery.2
It is responsible for 25% of  maternal deaths worldwide.5 
The incidence of  post-partum haemorrhage (PPH), is 
higher in low-resource countries than the rest of  the 
world.5  In Nigeria in a study done in North-Central Zone, 
post-partum haemorrhage was responsible for 34.6% of  
maternal mortality.6
The causes of  mortality are multi-factorial, and preven-
tion requires a multi-disciplinary response.7 The most 
common cause of  PPH is uterine atony which accounts 
for 70% of  cases leading to severe postnatal anaemia and 
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Oxytocin is a cyclic nona-peptide that stimulates the up-
per segment myometrium to contract rhythmically, con-
stricts spiral arteries and decreases blood flow through 
the uterus.9 Thus, it is an effective first-line treatment for 
post-partum haemorrhage.10  The effectiveness of  oxyto-
cin titration for the prevention of  PPH in at risk wom-
en is not in doubt. However, the lack of  power supply 
for appropriate storage of  oxytocin and the absence of  
non-parenteral routes of  administration of  the drug are 
important factors limiting its optimal use in rural com-
munities in Nigeria. These challenges herald the need for 
alternatives.
However, whether misoprostol which is also an active 
uterotonic agent that allows the uterus to contract within 
a few minutes11,12,13 with added advantages of  being rel-
atively stable at room temperature, inexpensive, rapidly 
absorbed into the circulation after rectal administration, 
and not requiring much skill is as effective and safe as 
oxytocin titration in preventing PPH in at risk women af-
ter active management of  third stage of  labour (AMTSL) 
is unclear. 
The objective of  this study therefore, was to compare the 
safety and efficacy of  adjunctive rectal misoprostol and 
intravenous oxytocin titration for prevention of  post-par-
tum haemorrhage in at risk patients, after routine active 
management of  the third stage of  labour. For this study 
adjunctive rectal misoprostol was defined as insertion of  
600ug of  misoprostol per rectum after routine manage-
ment of  third stage of  labour.
The study hypothesized that there was no difference in 
effectiveness and safety between rectal misoprostol and 
oxytocin titration in the prevention of  post-partum hae-
morrhage in at risk patients. It is expected that the find-
ings from this research would contribute towards answer-
ing the research question: Is rectal misoprostol as safe 
and effective as intravenous oxytocin titration for the pre-
vention of  primary post-partum haemorrhage in at risk 
patients after routine AMTSL?
 
Materials and method
This study was conducted at the University of  Abu-
ja Teaching Hospital to compare the effectiveness and 
safety of  adjunctive rectal misoprostol (cases) with in-
travenous oxytocin titration (control) for prevention of  
postpartum haemorrhage in at risk patients after routine 
active management of  the third stage of  labour.
 The hospital is a 350 bed Federal tertiary health facility 
that provides health care services to the inhabitants of  
Abuja and neighbouring states. Abuja’s total population 
is estimated to be about 6 million in 2017. The obstetric 
unit has a total of  38 beds, while the labour ward has 
12 delivery beds. About 2,500 deliveries are conducted 
annually.
The study population was comprised of  consecutive 
women in labour who were at risk of  PPH. Awareness 
about the study was created at the Antenatal clinic and 
written informed consent was obtained from each eligible 
patient following delivery of  the placenta when routine 
active management of  third stage would have been ef-
fected. The Research Ethics Committee of  the University 
of  Abuja Teaching Hospital approved the conduct of  the 
study.
Inclusion criteria
These included all parturients with predisposing factors 
to uterine atony who had given consent to be part of  
the study. The risk factors for uterine atony included: 
grand-multiparity, multiple gestation, precipitate labour, 
chorioamnionitis, polyhydramnios, fetal macrosomia, 
previous caesarean section, coagulation defect, previous 
PPH, induced/augmented labour and other medical con-
ditions like hypertension and diabetes
Exclusion criteria
This was done after recruitment but before interventions. 
These included patients with hematocrit less than 30% 
and those with any contraindications to prostaglandin 
use. Other exclusion criteria were those that presented 
in second and third stages of  labour as well as those who 
had episiotomy, perineal lacerations and cervical lacera-
tion.
Sample size determination
The primary outcome measure for this study was 
post-partum blood loss of  equal to or more than 500 ml. 
The sample size of  122 women for both arms of  the 
study was calculated using the formula for calculation of  
sample size for case control studies with dichotomous 
primary outcome14 on the following assumptions:
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- Sample size adjustment for dropout of  10 %.
-Oxytocin titration would prevent PPH in 93.2% based 
on report from a previous study15
-The study was designed to detect a difference of  20% 
(effect size) before it can be considered to be clinically 
significant.
-Significance level of  5% for the hypothesis test and a 
power of  80 per cent (or 0.8).
Methods of  allocation into study groups/interven-
tions
A total of  one hundred and twenty-two women with risk 
factors for uterine atony were recruited. All the proce-
dures were carried out by the researchers and, the re-
search assistants who had been trained on measurement 
of  blood loss. 
Blood samples were taken for pre-delivery hematocrit es-
timation, and grouping and cross-matching of  blood. 
Allocation into two study groups was achieved using 
computer-generated list by a statistician who was not 
part of  the investigators. A slip of  paper allocating the 
patient into either of  the two study groups was placed 
in sequentially numbered, opaque, sealed envelopes indi-
cating their medication. One group of  patients received 
600μg of  misoprostol rectally (Group 1) while the other 
group received 20IU of  oxytocin (Rotexmedica) in 500ml 
of  Normal saline water infusion at a rate of  30 drops per 
minute to last 4 hours after routine management of  the 
third stage of  labour (Group2). The latter is the standard 
of  care in the study setting for the prevention of  PPH 
among high risk women after active management of  third 
stage of  labour.
Immediately after delivery of  the baby, administration of  
intramuscular 10IU of  oxytocin, clamping and division 
of  the cord, a new delivery towel (Nightingale) weighing 
0.1kg was placed beneath the perineum before the deliv-
ery of  placenta in order to eliminate the liquor.  After the 
delivery of  placenta by controlled cord traction, uterine 
massage was done and thereafter those in the misopros-
tol group had 600μg of  misoprostol administered rectally 
while in the second group, oxytocin titration was com-
menced.   
The patients were monitored in the labour ward for 2 
hours.  All the soaked drapes and pads were weighed and 
the old weight was subtracted from the new weight. A 
hundred gram increase in weight was considered to be 
equivalent to 100ml of  blood loss (assuming specific 
gravity of  blood equivalent to 1gm/ml)16.          
                   
The initial measurement was after delivery of  the pla-
centa. Subsequently, patients had hourly measurement 
of  the delivery towel/pad twice before being transferred 
to the maternity ward, where monitoring was continued 
for twenty-four hours. Each pad removed by the pa-
tient within the first 24 hours of  delivery while still in 
the maternity ward was also weighed and the difference 
in weight calculated as already stated. The weighing was 
carried out by any member of  the team of  researchers. 
Post-delivery blood sample was taken 24 hours after de-
livery to determine the hematocrit before discharge. Data 
was prospectively collected using a structured proforma.
Primary and secondary outcome measures
The primary outcome measure was development of  post-
partum haemorrhage while secondary outcome measures 
included; significant change in pre and post delivery hae-
matocrit, severe post partum haemorrhage, the need for 
additional uterotonics, blood transfusion and medication 
side effects.
Data analysis
Data was analysed using statistical package social scienc-
es (SPSS Version 16). Categorical variables were analysed 
using Chi2 – test, Mann Whitney and Fishers exact test 
were used for comparison of  means where appropriate. 
A P-value of  less than 0.05 was accepted as indicating 
statistical significance.
Results
The result of  the study is as shown in the consort flow 
diagram (Figure 1). A total of  122 women with risk fac-
tors for PPH were allocated to receive either, adjunctive 
rectal misoprostol(cases), (n=61) or oxytocin titration, 
(control) (n=61) after active management of  the third 
stage of  labour. However, it was only 110 patients (miso-
prostol, n=56) and (oxytocin titration n=54) that were 
eventually analysed, following exclusion of  12 women 
that either had cervical laceration (n=2) or perineal lacer-
ations (n=10). None of  the patients opted out after giv-
ing consent and recruitment.
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The baseline characteristics of  the participants were sim-
ilar for both groups as shown in table 1. The results with 
respect to the selected risk factors for PPH for the two 
groups are also shown in table 1. No statistically signifi-
cant difference was obtained between the groups for any 
of  the risk factors. 
When the mean estimated blood loss measurements were 
compared, there was a relatively higher blood loss among 
the misoprostol group (457.6±377.5ml), than recorded in 
the oxytocin group (440.4± 301.8ml). However, this dif-
ference was not statistically significant (P = 0.712). There 
was also a marginal higher incidence of  PPH in the miso-
prostol group (19.6%) compared to18.5% in the oxytocin 
group. This difference just like in the former was also not 
statistically significant (P=0.902).
Figure 1: CONSORT Flow Diagram 
 
Assessed for eligibility (n= 416) 
Excluded (n=294   ) 
♦ Not meeting inclusion criteria (n=287  ) 
♦ Declined to participate (n=7  ) 
 
Analysed (n=56)  
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Discontinued intervention (n=0) 
Allocated to intervention: 
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The mean pre-delivery haematocrit was 31.9 %( Group 
1) versus 31.8 %( Group 2) while the mean post-delivery 
haematocrit was 30.5 %( Group1) versus 30.8 %( Group 
2). 
There were no significant differences either in the pre- 
delivery, post –delivery and changes in haematocrit 
percentages in the two groups. (P = 0.995, 0.676, and 
0.861respectively).
We observed no statistically significant difference (P= 
0.789) in the proportion of  women with post-partum 
blood loss of  >1000 mls between the misoprostol (n = 5; 
8.9%) and oxytocin (n= 4; 7.4%) groups (Table 2).
Table 1: Baseline characteristics of the study participants 
  
Parameter    Rectal Misoprostol   Oxytocin 20IU             p-value 
      600ug N=56(%)  500ml    
         Normal/Saline 
         N=54(%)      
  
Age(years) mean+ SDa    28.3+4.4  28.1+ 3.4   0.618 
           - 
Bookedb    44(78.6)  43(79.4)   0.539 
  
Unbookedb     12(21.4)  11(20.4)   0.912 
    
Nulliparab    12(21.4)  6(11.1)              0.309 
  
Multiparab    44(78.6)  48(88.9)   0.674 
  
Gestation in weeks   39.9+ 1.9  38.8+ 1.5   0.627 
Mean+ SDa 
  
Twin gestation               1(1.8)   2(3.7)    0.618 
  
Induction of labour    17(30.4)  12(22.2)   0.533 
  
Oxytocin Augmentation  23(41.1)  23(42.6)   0.918 
  
Magnesium Sulphate              4(7.1)   4(7.4)    0.960 
  
Fetal macrosomia    1(1.8)   2(3.7)    0.980 
  
Antepartum haemorrhage  2(3.6)   2(3.7)    0.972 
  
Previous caesarean   2(3.6)   5(9.3)    0.439 
  
Fibroid in pregnancy               1(1.8)   1(1.9)    0.980 
  
Chorioamnionitis    1(1.8)   2(3.7)    0.618 
Mann-Whitneya ,  Fishers exact testb  Chi-squarec 
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Table 2: Primary and secondary outcomes measures indicative of blood loss. 
  
Parameters    Rectal             Oxytocin 20IU          p-value 
Misoprostol 600ug              in 500ml  
       N=56(%)   Normal/Saline  
         N=54(%)     
        
    
Average EBL in ml           457.6+ 377.5                     440.4+ 301.8  0.712 
  
EBL>500ml< 1000mlc            11(19.6)                       10(18.5)  0.902 
  
EBL≥1000mlc            5(8.9)            4(7.4)            0.789 
  
Pre-delivery Haematocrita           31.9+2.14           31.8+ 1.9  0.995 
  
Post-delivery Haematocrita          30.5+ 2.40           30.8+2.7            0.676 
  
Change in Haematocrita            1.6+ 1.90          1.4+1.6   0.086 
  
Additional Uterotonicc           7(12.5)                     6(11.1)   0.841 
  
Blood Transfusion            1(1.7)                         -    
  
Mann-Whitneya ,  Chi-squarec 
Comparable proportion of  women 7(12.5%) in the miso-
prostol group versus 6(11.1%) in the oxytocin group re-
quired additional uterotonics. This marginal variation was 
not statistically significant. Only one patient in the miso-
prostol group had blood transfusion. 
 Secondary outcome measures did not show any signif-
icant difference specifically in relation to severe PPH 
(EBL>1000mls), additional uterotonics and blood trans-
fusion.
Considering the patients with regards to adverse effects 
of  the drugs, none of  the patients in the two groups had 
nausea and vomiting. Of  particular interest was the inci-
dence of  shivering which was higher (7.1%) in the miso-
prostol group as against (1.9%) in the oxytocin group. 
This difference was not statistically significant (P=0.37). 
Pyrexia greater than 37.5o C was more commonly ob-
served among the misoprostol group, 25(45%) compared 
to 5(9.2%) in the oxytocin group and the difference was 
found to be statistically significant (P=0.002). This is 
shown in table 3.
Table 3: Medication side effects 
 
Parameterb        Rectal Misoprostol       Oxytocin 20IU in            p- value 
                                           600ug             500ml, Normal/Saline  
           N=56(%)                       N=54(%)          
          
       
Shivering         4(7.1)           1(1.9)    0.366 
  
Temperature > 37.5o C      25(45)           5(9.2)    0.002 
  
                                                         Fishers exact testb      
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Discussion
In low to middle income countries (LMICs) like other 
parts of  the world, post-partum haemorrhage is regarded 
as one of  the major causes of  maternal morbidity and 
mortality.1 Active management of  the third stage of  la-
bour with the parenteral administration of  oxytocin as 
the most important step has been widely recommended 
for the prevention of  PPH.2  Studies on adjunctive treat-
ment for at risk patients after AMTSL for prevention of  
PPH is crucial towards further reduction of  PPH espe-
cially in LMICs.
The incidence of  PPH in the misoprostol group was 
19.6% which was similar to 18.5% observed in the oxy-
tocin group and comparable with 22.2% Versus 20.9% 
respectively reported by Badejoko et al in South West Ni-
geria.17 This study demonstrated that there was no signif-
icant difference in the incidence of  PPH in both groups 
and is also comparable to findings from previous quoted-
study.17
The higher incidences of  PPH recorded in our study as 
well as in the earlier study conducted in Nigeria utilizing 
adjunctive uterotonics after AMTSL17 affirms the magni-
tude of  PPH in Nigeria to be high. This finding suggests 
that the incidence of  PPH may have been much higher 
in this obstetric population in the absence of  adjunctive 
uterotonics since all the patients had AMTSL.  
There was no difference in the mean haematocrit values 
observed. The mean pre- delivery haematocrit, post –de-
livery haematocit, and change in haematocrit were not 
statistically significantly different between the two groups. 
These findings on the post haematocrit values have there-
fore corroborated the results of  the estimated blood loss 
to be true since the post haematocrit value should be a re-
flection of  the estimated blood loss. Blood losses <500ml 
usually do not result in significant drop in haematocrit.18
The limited use of  blood transfusion which was done for 
only one patient in the misoprostol group was not unex-
pected as the mean post delivery haematocrit for both 
groups were above the reference range for anaemia which 
suggests that majority of  the patients were stable and that 
the adjunctive treatments may have helped in preventing 
further blood loss amongst patients who developed PPH.
The absence of  nausea and vomiting in both groups may 
have emanated from the point of  view that both drugs 
were not administered using the oral route that possesses 
those familiar side effects. This finding may make either 
of  the drugs more appealing to the patients when there is 
need for the use of  either agent. 
The recorded higher incidence of  shivering and pyrexia 
in this study among the misoprostol group is in keep-
ing with previous studies on the use of  misoprostol for 
prevention and treatment of  PPH.17,19,20,21,22 Shivering and 
pyrexia from misoprostol are expected due to prostaglan-
din E effects on central thermoregulation centre.16
This study has shown no statistical significant difference, 
in efficiency and safety between rectal misoprostol and 
oxytocin infusion in the prevention of  PPH, after routine 
management of  third stage of  labour in patients at risk 
of  PPH. However, rectal misoprostol was associated with 
fever which was self-limited.
This efficacy and safety demonstrated by misoprostol, 
as an alternative to oxytocin infusion in preventing PPH 
in at risk women may be a welcome research finding. It 
will allow its guided use in developing countries and low 
resource settings where oxytocin infusion can be cum-
bersome especially in the rural communities where there 
is dart of  human resources. This finding has a tendency 
to support the wide spread marketing of  misoprostol in 
rural health care clinics/hospitals in developing countries 
like ours, due to its ease of  administration by even non-
skilled personnel towards reduction in the incidence of  
PPH.
The study is however limited by the fact that neither the 
patients nor investigators were blinded as regards the in-
terventions. The small sample size may limit its general-
izabilty thereby signaling the need for larger studies to 
investigate this important subject towards reducing ma-
ternal morbidity and mortality from PPH in developing 
countries.
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